Radiation dosimetry of [ 18 F]VAT in nonhuman primates by Karimi, Morvarid et al.




Radiation dosimetry of [ 18 F]VAT in nonhuman
primates
Morvarid Karimi
Washington University School of Medicine in St. Louis
Zhude Tu
Washington University School of Medicine in St. Louis
Xuyi Yue
Washington University School of Medicine in St. Louis
Xiang Zhang
Washington University School of Medicine in St. Louis
Hongjun Jin
Washington University School of Medicine in St. Louis
See next page for additional authors
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Karimi, Morvarid; Tu, Zhude; Yue, Xuyi; Zhang, Xiang; Jin, Hongjun; Perlmutter, Joel S.; and Laforest, Richard, ,"Radiation
dosimetry of [ 18 F]VAT in nonhuman primates." EJNMMI.5,. 73. (2015).
http://digitalcommons.wustl.edu/open_access_pubs/4443
Authors
Morvarid Karimi, Zhude Tu, Xuyi Yue, Xiang Zhang, Hongjun Jin, Joel S. Perlmutter, and Richard Laforest
This open access publication is available at Digital Commons@Becker: http://digitalcommons.wustl.edu/open_access_pubs/4443
ORIGINAL RESEARCH Open Access
Radiation dosimetry of [18F]VAT in
nonhuman primates
Morvarid Karimi1*, Zhude Tu2, Xuyi Yue2, Xiang Zhang2, Hongjun Jin2, Joel S. Perlmutter1,2,3,4,5 and
Richard Laforest2
Abstract
Background: The objective of this study is to determine the radiation dosimetry of a novel radiotracer for vesicular
acetylcholine transporter (−)-(1-((2R,3R)-8-(2-[18F]fluoro-ethoxy)-3-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)piperidin-
4-yl)(4-fluorophenyl)-methanone ([18F]VAT) based on PET imaging in nonhuman primates. [18F]VAT has potential for
investigation of neurological disorders including Alzheimer’s disease, Parkinson’s disease, and dystonia.
Methods: Three macaque fascicularis (two males, one female) received 185.4–198.3 MBq [18F]VAT prior to whole-body
imaging in a MicroPET-F220 scanner. Time activity curves (TACs) were created from regions of interest (ROIs) that
encompassed the entire small organs or samples with the highest activity within large organs. Organ residence times
were calculated based on the TACs. We then used OLINDA/EXM 1.1 to calculate human radiation dose estimates based
on scaled organ residence times.
Results: Measurements from directly sampled arterial blood yielded a residence time of 0.30 h in agreement with the
residence time of 0.39 h calculated from a PET-generated time activity curve measured in the left ventricle. Organ
dosimetry revealed the liver as the critical organ (51.1 and 65.4 μGy/MBq) and an effective dose of 16 and 19 μSv/MBq
for male and female, respectively.
Conclusions: The macaque biodistribution data showed high retention of [18F]VAT in the liver consistent with
hepatobiliary clearance. These dosimetry data support that relatively safe doses of [18F]VAT can be administered to
obtain imaging in humans.
Keywords: [18F]VAT, PET, Dosimetry, Primate, Vesicular acetylcholine transporter
Background
Cholinergic neurotransmitters play an important role inbrain
function. Striatal cholinergic interneurons modulate the
function of dopaminergic and glutamatergic inputs to stri-
atum fromother brain regions including the substantia nigra,
thalamus, and cortex. Cholinergic projections also target
other brain regions including the hippocampus, cerebellar
vermis, and thalamus. Mounting evidence implicates abnor-
malities in cholinergic systems in numerous neurological
conditions such as Parkinson’s disease (PD), dystonia, and
Alzheimer’s disease (AD). Alterations in cholinergic function
could contribute to involuntary movements that develop in
people with PD called L-dopa-induced dyskinesias (LID).
Indeed, selective nicotinic acetylcholine receptor partial ago-
nists can reduce LID, while extending the duration of motor
benefits in nonhuman animal models of PD [1, 2]. Choliner-
gic neurons in the pedunculopontinenucleus (PPN) and their
thalamic efferent terminals could be involved in postural in-
stability in PD [3]. Furthermore, changes in nicotinic acetyl-
choline receptorsmay correlate with cognitive dysfunction in
PD [4, 5]. Thewell-knownclinical response to anticholinergic
medications in dystonia suggests pathologic involvement of
cholinergic neurons. In fact, one geneticmousemodel of dys-
tonia has increased endogenous cholinesterase activity in stri-
atum with impaired long-term depression that can be
improved by blocking acetylcholine receptors [6]. Finally, the
severity of cognitive dysfunction in AD correlates with loss of
cholinergic neurons in CNS [7]. Indeed, the basal forebrain
has showed marked loss of cholinergic neurons in AD aut-
opsy studies [8].
* Correspondence: morvaridk@npg.wustl.edu
1Department of Neurology, Washington University Medical School, St. Louis,
MO 63110, USA
Full list of author information is available at the end of the article
© 2015 Karimi et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
Karimi et al. EJNMMI Research  (2015) 5:73 
DOI 10.1186/s13550-015-0149-4
In vivo measurement of cholinergic neurons could be
critical for understanding the pathophysiology of these
neurologic conditions. A PET radiotracer that permits
quantification of loss of cholinergic neurons would provide
a useful tool for assessing the pathophysiological correlates
of cognitive and motor symptoms. Measurement of the
vesicular cholinergic transporter (VAChT) has the potential
to provide means to quantify cholinergic neurons. VAChT
is expressed in presynaptic cholinergic terminals. We have
preclinical data demonstrating the potential of (−)-(1-
((2R,3R)-8-(2-[18F]fluoro-ethoxy)-3-hydroxy-1,2,3,4-tetrahy-
dronaphthalen-2-yl)piperidin-4-yl)(4-fluorophenyl)-metha-
none ([18F]VAT) as a VAChT radiotracer that has high
brain uptake with excellent selectivity and specificity [9,
10]. The objective of this study is to calculate human radi-
ation dosimetry estimates of [18F]VAT based on nonhuman
primate studies. This will permit us to better estimate
allowable [18F]VATactivity for use in human PET imaging.
Methods
Radiopharmaceutical preparation
The radiosynthesis for [18F]VAT was accomplished using a
two-step procedure in a Good Manufacturing Practice
(GMP) facility. We prepared [18F]fluoroethyl tosylate using
an Eckert and Ziegler Modular-Lab system in the first step
[11–13]. We synthesized [18F]VAT using a GE TRACERlab
FX-N module as [18F]fluoroethyl tosylate reacted with the
corresponding enantiopure phenol VAT precursor. The final
product was purified by a reverse phase HPLC prior to for-
mation of the injection dose using 10 % of ethanol in sa-
line. The radioactive dose was authenticated by a quality
control analytical HPLC system.
All procedures were approved by Animal Studies
Committee of Washington University in St. Louis.
Anatomical MRI
Each animal was anesthetized as described above and
underwent a head, chest, abdominal, and pelvic T1-
weighted MR and T2 with a Siemens 3T Trio scanner
using a knee coil at least a week apart from the PET ses-
sion. We used the MRIs as a guide to identify the location
of the critical anatomical structures including the brain,
heart, lungs, liver, gallbladder, spleen, kidneys, large and
small intestines, bladder, and gonads.
Nonhuman primate radiation dosimetry
Two males and a female macaque fascicularis underwent
whole-body scan in a Siemens MicroPET-F220. The female
macaque was scanned twice. The macaques were prepared
as previously described [14, 15]. The macaques were fasted
overnight before each study. Each animal was initially anes-
thetized with ketamine 10–15 mg/kg i.m. They also re-
ceived glycopyrrolate i.m. to reduce secretions. A 20-gauge
plastic catheter was inserted into a limb vein to permit
radiotracer; another 20-gauge plastic catheter was inserted
into a femoral artery for arterial blood sampling (first scan
of the female macaque); and a soft-cuffed endotracheal tube
was inserted into the trachea to permit ventilation with iso-
flurane to maintain anesthesia. Lacrilube was placed into
the animal’s eyes to protect the corneas, and eyelids were
taped shut. Pulse, end-tidal PCO2, and rectal temperature
were monitored. We used surgical tape to secure the head
position of the anesthetized animal. The torso was wrapped
in a warming blanket, and surgical tape was used to keep
the torso in place. The transaxial positioning of the scan-
ning bed is computer controlled within 0.2-mm tolerances
permitting repeated repositioning of the animal for transax-
ial emission and transmission scans at multiple levels.
Data acquisition
The animals weighed 7.3 (male), 6.4 (male), and 4.5 (female)
Kg and received 185.4, 187.2, and 198.3 MBq of [18F]VAT,
respectively, with >74 GBq/μmol specific activity. The fe-
male animal was scanned twice and received 197.6 MBq for
the second scan. Biodistribution data of [18F]VAT were ob-
tained from sequential whole-body PET images. Prior to
radioligand injection, we collected four 30-min transmission
scans using a Co-57 point source to cover four body sec-
tions: A (whole brain), B (heart and lungs), C (liver, gallblad-
der, and kidneys), and D (urinary bladder, small and large
intestines). Seven to eight successive PET scans were done
for each of the four sections (Fig. 1) immediately following
[18F]VAT injection. Arterial blood samples were obtained
for the first study in the female animal over a total scan-
ning time of approximately 4 h. Most of the samples were
taken in the first 3 min to ensure adequate description of
the arterial time activity curve. Total radioactivity content
in each blood sample was measured in a well counter
cross-calibrated with the MicroPET-F220.
Fig. 1 Seven to eight successive PET scans of increasing duration
were obtained to cover A (whole brain), B (heart and lungs), C
(liver, gallbladder, and kidneys), and D (urinary bladder, small and
large intestines)
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Data analysis
We coregistered each emission scan to the correspond-
ing transmission scan and could further confirm that
there were no changes in the positioning between trans-
mission and emission scans. Sinogram data were col-
lected after [18F]VAT injection and reconstructed using
filtered back projection with a ramp filter at Nyquist fre-
quency along with correction for scatter, random, at-
tenuation, and dead time. Reconstructed resolution was
<2.0-mm full width half maximum for all three dimen-
sions at the center of the field of view. PET image
counts were calibrated to a dose calibrator to convert
measured PET uptake to MBq of F-18. For some organs
(whole brain, heart, lungs, urinary bladder), regions of
interest (ROIs) were drawn to entirely encompass the
target organ using ASIPro VM™ MicroPET analysis soft-
ware (Siemens PreClinical Solutions, Knoxville, TN). For
others (liver, spleen, small intestines, kidney, and gall-
bladder), we could not delineate a region large enough
without including neighboring organs. Hence, we chose
several small ROIs with the highest radioactivity within
the target organ. The appropriateness of these ROIs was
confirmed by comparison with the anatomical MRIs.
The average radioactivity concentrations of these ROIs
were multiplied by the entire organ weight to give an
estimate of the radioactivity within the total organ. This
approach will lead to slight underestimation of the
values. However, as we are sampling the subregions with
the most uptake and generalizing it to the entire organ,
this underestimation is overcorrected.
The calculated activity in the whole organ was plotted
as a function of time to yield the organ time activity
curves. Organ residence times were computed from the
analytical integration of the multi-exponential fit with
two exponentials on the decay corrected time activity
curves using GraphPad Prism6 software.
For the bladder, the cumulative activity was fitted by
an uptake function of the form: F(t) =A0*(1-exp(−A1.t)
where A0 and A1 were fitting parameters representing
the filling fraction and filling constant. These parameters
were entered in OLINDA MIRD bladder voiding model
under the assumption that the bladder is emptied every
2 h. For the small intestines, we used the linear fit for
the decay uncorrected time activity curve. The area
under the curve was calculated with the trapezoid
method.
The blood time activity curve for nonhuman primate
data was integrated using the trapezoid method to yield
the blood residence time. The blood activity was con-
verted to percent injected dose (198.3 MBq) in the ani-
mal assuming a density of 1 g/cm3 and blood volume of
8 % of the animal body weight [16]. Finally, 5 % of the
blood volume [17] was assumed to be present in the left
ventricle at all times.
The maximum theoretical residence time (T1/2/ln(2) or
2.64 h for F-18) minus the sum of measured residence
times was assigned to the remainder of the body as nonspe-
cific activity. No loss of urine or fecal matter was observed
in these animals during the scans. The calculated residence
times were scaled following this equation: scaled T(human)
=T(animal) × [(M_organ (human))/(M_total (human))]/
[(M_organ (animal))/(M_total (animal))]. We used human
male and female organ weights in OLINDA/EXM [18] for
the adult male and adult female models. We applied per-
centage body weight for male and female macaque fascicu-
laris for the kidney, liver, spleen, and heart as reported
previously [19]. We used the gallbladder, bladder, and intes-
tine percentage body weights of male and female macaque
fascicularis we had euthanized in the past. We calculated
macaque male and female organ weights for the brain and
lungs based on their measured volume assuming a density
of 1 g/cm3. The scaled human residence times were entered
in the program OLINDA/EXM 1.1 for F-18 following the
adult human male and female anthropomorphic models.
Results
Nonhuman primate biodistribution
Figure 2 shows the time activity curves compiled from
sequential imaging of a male macaque. The time activity
data were fitted with a function composed of single or
two exponentials. Least square minimization was per-
formed to find the best fitting parameters. We observed
a predominant accumulation of the activity in the liver,
brain, heart wall, and kidneys with initial fraction at ~30,
~8, 4, and 4 % of the injected dose, respectively, followed
by a slow clearance.
Residence times and dosimetry from nonhuman primate
biodistribution data
We averaged the values of the two measurements for
the residence time in the female macaque (Table 1).
The low standard deviation suggests good reproduci-
bility. We had only one measurement of the male
gallbladder as the top slices of the abdomen were not
captured in the PET scan of the second male ma-
caque. Directly collected arterial blood sampling was
done only for the female monkey as shown in Fig. 3
and yielded a residence time of 0.30 h. This was in
agreement with the residence time of 0.39 h calcu-
lated from a PET-generated time activity curve mea-
sured in the left ventricle.
We calculated organ dosimetry based on its residence
times with OLINDA/EXM 1.1 for the human adult
male and female model as presented in Table 2. The ef-
fective dose and effective dose equivalent for human
male and female adults are presented in Table 3.
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Fig. 2 Tissue activity curves with activity expressed in percentage of injected dose per organ
Table 1 Organ residence times in hour
Organ Residence time (h) Residence time (h)
Average two males ± SD Average two measures in one female ± SD
Liver 0.32 ± 0.03 0.33 ± 0.12
Heart wall 0.05 ± 0.004 0.03 ± 0.004
Brain 0.09 ± 0.02 0.11 ± 0.01
Lungs 0.08 ± 0.04 0.05 ± 0.005
Gallbladder 0.01 0.01 ± 0.0008
Kidneys 0.04 ± 0.0002 0.04 ± 0.01
Spleen 0.02 ± 0.00004 0.02 ± 0.002
Small intestine 0.06 ± 0.02 0.04 ± 0.008
Entire blood 0.44 ± 0.06 0.39 (PET)
0.30 (art line)
Urinary bladder 0.08 ± 0.04 0.08 ± 0.01
Blood assigned to the left ventricle 0.02 0.02
Remainder of the body 1.76 1.30
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Discussion
The nonhuman primate measures may reasonably predict
safe dosimetry levels for subsequent human exposures.
These studies better predict human exposure dosimetry
than rodent studies since metabolism may be quite differ-
ent. For example, rodents do not have a gallbladder, and
those radiopharmaceuticals that undergo liver metabolism
may have gallbladder as a critical organ with a relatively
high radiation exposure [20]. This would be completely
missed in rodents whereas studies in nonhuman primates
will capture this. Thus, these nonhuman primates provide
a critical step that provides an additional margin of safety
for radiopharmaceutical development and implementation
in humans.
The availability of suitable radiopharmaceuticals for
measuring VAChT in human brain is particularly im-
portant. VAChT may be involved in several diseases in-
cluding dystonia, Parkinson’s disease, schizophrenia, and
Huntington’s disease [21, 22]. These radiotracers also
may provide measurements of target engagement for
therapeutic interventions. [18F]VAT provides another
radiopharmaceutical option that may have advantages
over [18F]-FEOBV based upon better uptake in the brain
[10].
Conclusions
We used PET measures of radioactivity in organs and
direct arterial blood sampling to calculate dosimetry
exposure after the iv injection of [18F]VAT in nonhuman
primates. The liver was the critical organ with radiation
dosimetry of 51.1 μGy/MBq for males and 65.4 μGy/
MBq for females. We calculated an effective dose of 16
and 19 μSv/MBq for male and female, respectively.
Given the relatively low exposure to gonads and bone
marrow (radiosensitive organs), we should be able to
inject up to 764 MBq under the 21 CFR 361.1 guidelines
(<50 mSv to any organ, <30 mSv to radiation sensitive
organs).
Fig. 3 Tissue activity curves for blood based on PET-measured activity in the left ventricle and arterial blood sampling. Note that PET cannot
capture the rapid rise of blood activity occurring in the first 50 s following the iv [18F]VAT injection
Table 2 Extrapolated human radiation dose estimates for
[18F]VAT in microgray/megabecquerel





Lower large intestine 12.6 15.6
Small intestine 34.1 30.5
Stomach 12.6 15.7








Red marrow 10.4 12.7






Urinary bladder 33.7 52.3
Uterus 17.2
Total body 12.3 15.3
Data in italics represent critical organs
Table 3 Effective dose and effective dose equivalent for human
from nonhuman primate biodistribution data
Male Female
Effective dose (μSv/MBq) 16 19
Effective dose equivalent (μSv/MBq) 20 25
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